Long-Term Study Demonstrates Benefits Of Medtronic’s AdaptivCRT
This article was originally published in The Gray Sheet
Executive Summary
Complete results of the Adaptive CRT study released at the Heart Failure Society of America conference confirm that Medtronic’s AdaptivCRT cardiac resynchronization therapy reduces heart failure hospitalizations compared to regular echo-guided biventricular pacing.
You may also be interested in...
Medtronic Claims Clinical, Cost Advantages For Just-Launched Viva CRT-D
Viva is the first of Medtronic’s U.S. CRT-Ds to incorporate the proprietary AdaptivCRT algorithm designed to more readily adapt to a patient’s condition and optimize therapy. The firm also launched its Evera ICD last week.
Bridge Too Far? BMS Launch Plan For Sotyktu Pressured By Prospect Of Medicare Price Controls
With price controls in Medicare looming nine years after approval, launch strategies such as ‘bridge’ programs that build initial volume with free drug may have to be adjusted.
Are Regulators Ready For The Robot Era? ChatGPT Weighs In On EU Regulation
Artificial intelligence model’s comments signal the likely start of computer-generated comments to the US FDA’s public notices.